AstraZeneca PLC ADR

AstraZeneca PLC ADR is a global pharmaceutical company headquartered in Cambridge, UK. It is focused on the scientific discovery, development, and commercialisation of prescription medicines in specific areas including oncology, CVRM (cardiovascular, renal, and metabolism), respiratory infection, neuroscience, and gastroenterology. The company was established in 1999, following a merger between the Swedish company Astra AB and the British company Zeneca Group PLC. AstraZeneca operates in more than 100 countries, and its medicines are used by millions of patients worldwide. As of 2021, the company has 175 projects in the pipeline, with 17 new molecular entities in its late-stage pipeline. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialise small molecule medicines for obesity. AstraZeneca stock is traded on the NASDAQ under the ticker AZN. In 2020, the company developed the Oxford-AstraZeneca Covid-19 vaccine, which was approved for use in the UK in December of that year. In November 2021, the company unveiled a £1bn new research and development centre that will house 16 laboratories and 2,200 scientists, making it the largest science lab in the UK and the pharmaceutical company's largest single-site investment to date. Keep track of AZN share price movements via your eToro watchlist.